Sajith Wickramasekara
Co-founder & CEO, Benchling. On 3 shows, 3 appearances, plus 1 compilation re-air not counted. The Shows tab opens the full record on each.
founderexecutiveengineer@sajithw ↗LinkedIn ↗benchling.com ↗
Sajith Wickramasekara co-founded Benchling in 2012 while studying computer science at MIT, building a cloud informatics platform to replace paper lab notebooks and spreadsheets in life sciences R&D. Under his leadership, Benchling became a prominent biotech software unicorn serving hundreds of thousands of scientists across global pharmaceutical and biotechnology companies.
3shows
3appearances
61statements
9resolved
8supported
0contradicted
89%fully supported
Everything Sajith Wickramasekara said on any show that made the record, most notable first. Each card names its show and opens the statement there.
Wickramasekara: Major pharma increasingly licenses drug molecules from China
“We've seen this huge uptick in pharma going to China and buying molecules that they typically would have bought from American biotechs.”
Wickramasekara: Clinical trial optimization is a red herring versus molecule quality
“People get very focused on clinical trials because they're like the biggest line item. And they're important, don't get me wrong, but I think it's actually a bit of a red, red herring. Where, ah, yes, there are operational problems. Like, some studies are desi…”
Wickramasekara: Clunky enterprise systems force pharma scientists to email sensitive IP
“A lot of these companies, they do have systems that exist, but they're quite clunky and not integrated. So the scientists resort to using email, and this is whatever email systems they have set up. Sometimes they're personal gmails as well.”
Wickramasekara: GLP-1s will probably be the best-selling drugs of all time
“And then all of a sudden, like we have this category defining medicine that's going to go on to probably be the best selling drug of all, all time.”
Wickramasekara: AI in scientific discovery will focus on augmentation over autonomy next 1-2 years
“While I would love for that to happen, and I'm maybe more optimistic on a longer time scale, we will get there. I think in the short term, I'm next one to two years, which, you know, already feels like an eternity in AI time. I'm a little bit more bullish on s…”
Wickramasekara: Most Biotech Researchers Are Not Yet Using Much AI in R&D
“Most people aren't really using that much AI and R&D yet. They all want to, they're primed to, but there's a lot of concerns about accuracy, IP, security, legal. And I think the farther you go from SF, the like, Larger those concerns, concerns get.”
Wickramasekara: Pure AI biology model companies must morph into biopharma
“I think it's unlikely, it's possible, but it's unlikely that sort of, hey, they're just gonna remain pure model companies who just do deals with pharma, where pharma, you know, pays them a hundred million dollars upfront or something like that, and they have f…”
Wickramasekara: 5 to 10 customers represent what an entire vertical industry needs
“I find that having five, 10 customers is actually like a pretty representative model for what the entire industry needs.”
Wickramasekara: 60% of Benchling customers' laboratory instruments are unconnected
“The last time we kind of ran one of these benchmarking exercises was that For our customers, 60% of their instruments are not connected.”
Wickramasekara: Vertical software markets are less competitive, risking loss of focus
“One thing actually that's probably worse about vertical companies is you, the markets are not as competitive as horizontal companies, and so you can get a little unfocused at times”
Wickramasekara: Advanced drug development lacks modern software and data infrastructure
“You would think that such deliberate advanced science would have a large amount of software and advanced data behind it as well, but that's actually not the case.”
Wickramasekara: Curing cancer with Excel is worse than dev without version control
“They're literally trying to cure cancer using Excel. This is the equivalent of one of the companies you work at building software without version control. It's honestly probably a little worse, actually.”
Wickramasekara: Applying standard data practices to life sciences requires little domain expertise
“Using quite standard data practices we were able to make a big dent in a really high impact field that touches everyone and it doesn't require a ton of domain expertise.”
Wickramasekara: Recent years in biotech equal a dot-com level bust
“We're probably like the last couple of years are probably like the equivalent of like the dot com bust happening for biotech.”
Wickramasekara: Novel biotech modalities are in a trough of disillusionment
“I think investors and companies got very excited and put a lot of money into these categories, and we're kind of in the trough of disillusionment for some of them now.”
Wickramasekara: Next decade of biotech will focus on speed and cost
“If the last decade was about sort of biologics and these new modalities, I think the next is going to be about speed and cost.”
Wickramasekara: Prescription drugs account for 9% of US healthcare spending
“I think nine percent of healthcare spent, prescription drug sales are nine percent of healthcare spending in the U.S.”
Wickramasekara: Obesity drugs were completely unfundable five years ago
“So GLP-Ins obviously have just transformed obesity as, like, a treatable disease when, by the way, it was, like, a totally unfundable category of things, like, five years ago.”
Wickramasekara: Much of scientific research is lost to institutional folklore
“And so there's so much of science that lives in like folklore and institutional knowledge, and that's kind of lost over time.”
Wickramasekara: High-stakes AI requires human accountability to bear legal liability
“And truthfully, like at the end of the day, you probably like, you know, with a radiologist, you probably need a human to be accountable For those decisions, it's not just about the technology. Like, someone, someone's gotta be there to, like get sued if somet…”
Wickramasekara: Biology AI has powerful models but lacks a ChatGPT-like interface
“I think we're like, we've got GPT, but there's no chat. Like, that, that's kind of how I think about it. Like, I think the chat, and I mean chat metaphorically, like, that was the interface that made things really take off in, in software. And I don't think it…”
Wickramasekara: 90% of vertical AI is workflow translation and building trust
“I think in a vertical, I think 90% of the work is actually, like, translation. It's taking something and making science, making sure scientists trust it, it's the right point in their workflow, it's easy to use, and it's accurate.”
Wickramasekara: Large pharma is piloting AI without organizational transformation yet
“Most of the
Large pharma at this point that I've worked with, like, you know, they've got co-pilot and things like that, and they're doing a lot of pilots of different technologies, but I haven't seen their orgs transformed yet.”
One line per show, most statements first. The link opens Sajith's full record on that show: the calibration, argument clarity, speaking style and every statement made there.
| Show | Role there | Eps | Statements | Record | |
|---|---|---|---|---|---|
 NO PRIORSLEDGER | Co-founder & CEO, Benchling | 1 | 33 | 100% 6/6 | full record on No Priors → |
 a16zLEDGER | Co-founder & CEO, Benchling | 1 +1 | 17 | 100% 2/2 | full record on the a16z Podcast → |
 MADLEDGER | Co-founder & CEO, Benchling | 1 | 11 | 0% 0/1 | full record on the MAD Podcast → |